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ABSTRACT
This study describes a real-time PCR assay for the detection and identiﬁcation of Bordetella pertussis and
Bordetella parapertussis. The assay is based on ampliﬁcation of a fragment from the repeat sequence
regions IS481 and IS1001 found in B. pertussis and B. parapertussis, respectively, with subsequent species
identiﬁcation by melting curve analysis using SYBR Green chemistry. Discrimination between the two
species was straightforward, as the corresponding melting points showed a signiﬁcant difference of 7C.
The assay was evaluated ﬁrst with reference strains and retrospective human clinical samples, and then
prospectively with 132 human clinical specimens received between April 2003 and December 2005. The
assay allowed the rapid detection of 22 positive clinical samples, of which 15, including one fatal case,
were not identiﬁed by standard culture techniques. The new assay was sensitive and speciﬁc, and can be
implemented easily using any real-time PCR apparatus.
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INTRODUCTION
A resurgence of pertussis infection has been
observed in France, with an increase to 642
clinical cases during the year 2000, of which nine
were fatal [1]. The number of infants hospitalised
has increased, and the presence of whooping
cough syndrome among other individuals present
in their environment has been noted. This disease
now affects young adults and teenagers who were
vaccinated >10 years previously, thus enabling
them to contaminate unvaccinated or incom-
pletely vaccinated children, who are thereby
exposed to severe forms of the disease. In this
adult and teenage population, the pertussis infec-
tion evolves readily into an atypical form that is
difﬁcult to diagnose, so that microbiological
conﬁrmation is necessary.
Molecular biological techniques provide
invaluable tools for the diagnosis of Bordetella
pertussis infection, and the use of PCR in reaching
a diagnosis has been recommended for several
years [2]. PCR is more sensitive than culture for
the detection of B. pertussis and Bordetella paraper-
tussis, especially during the late stages of the
disease and ⁄ or after antibiotic treatment has been
started [3]. Since 2001, numerous real-time PCR
techniques have been developed for the detection
and identiﬁcation of B. pertussis. Most of these
assays target the IS481 sequence [4–11], the toxin
gene [12,13] or the pertactin gene [14], and use
one of the three real-time detection formats
currently available, i.e., SYBR Green, TaqMan or
ﬂuorescence resonance energy transfer chemistry.
However, only two of the published assays used
SYBR Green chemistry and melting curve analysis
(MCA), amplifying the IS481 sequence and the
toxin promoter region, respectively [11,15]. Fol-
lowing the resurgence of whooping cough in
France, the present study describes the develop-
ment of a real-time PCR assay using SYBR Green
chemistry with the repeated IS481 sequences of
B. pertussis and the repeated IS1001 sequences of
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B. parapertussis as targets. Subsequent species
identiﬁcation was based on MCA. The advantages
of this new test are the relatively low cost (since
no probe is used) and the possibility of identify-
ing both of the above species in a single test.
MATERIALS AND METHODS
Bacterial strains
Several strains of Bordetella spp., including B. pertussis Sato
(CIP81.32), B. parapertussis 22651 L2 (CIP63.2), Bordetella bron-
chiseptica type strain 452 (CIP55.110) and Bordetella holmesii
type strain 5589 (CIP 104394), were used in this study and
were cultured on selective media as described below. Other
bacterial species isolated from clinical specimens and used to
determine the speciﬁcity of the PCR primers included Escheri-
chia coli, Salmonella Enteritidis, Salmonella Typhimurium,
Neisseria meningitidis, Haemophilus inﬂuenzae, Haemophilus para-
inﬂuenzae, Mycoplasma pneumoniae, Mycoplasma genitalium,
Streptococcus pneumoniae and Staphylococcus aureus. Genomic
DNA was extracted using the MagnaPure LC DNA Isolation
Kit I and the MagnaPure LC Isolation Station (Roche Applied
Science, Penzberg, Germany). DNA was stored at )20C until
required for analysis.
Nasopharyngeal aspirates
Twenty-nine frozen nasopharyngeal aspirates (NPAs), collect-
ed originally at the Children’s Hospital of Bordeaux between
June 1996 and March 2003 (male ⁄ female ratio, 0.52; mean age,
3.4 ± 3.3 months), were used for the retrospective study, of
which 17 were culture- and direct ﬂuorescent antibody test-
positive, and 12 were culture- and direct ﬂuorescent antibody
test-negative.
For the prospective study, 132 NPAs were used. Three
samples were received from private laboratories (male ⁄ fe-
male ratio, 0.33; mean age, 31.2 ± 26.1 years) and 129 were
obtained from neonates and infants between April 2003 and
December 2005 (male ⁄ female ratio, 0.51; mean age,
2.6 ± 7.2 years). The time between NPA collection and labor-
atory analysis was < 15 min. Once received, each NPA was
used to inoculate two selective media, Reagan Lowe medium
(charcoal agar; Oxoid, Basingstoke, UK) and Bordet Gengou
medium (Bordet Gengou agar base; Difco, Detroit, MI, USA),
supplemented with deﬁbrinated sheep blood 5% v ⁄v. The
plates were incubated at 37C and examined for 5 days for
colonies typical of B. pertussis or B. parapertussis. Representa-
tive colonies with typical Gram-negative coccobacilli mor-
phology were conﬁrmed by direct ﬂuorescent anti-B. pertussis
antibody tests (Bacto FA B. pertussis; Difco) and the API 20E
system (bioMe´rieux, Marne-la-Coquette, France) using a
MacFarland · 4 suspension. Each isolate was sent to the
French National Reference Centre for Bordetella (Pasteur
Institute, Paris, France) for conﬁrmation of species identiﬁca-
tion.
Genomic DNA was also extracted directly from each NPA
with the MagnaPure LC DNA Isolation Kit I and the
MagnaPure LC Isolation Station. DNA was stored at )20C
until required for analysis. Extracted DNA was tested both
undiluted and diluted 1:10 using the three PCRs described
below.
Design of the primers for PCR ampliﬁcation of the IS481,
IS1001 and 16S rDNA sequences
The available IS481 sequences of B. pertussis (GenBank acces-
sion numbers M28220, 66937, L26973, S66929 and M22031)
were aligned using multiple sequence alignment with hierar-
chical clustering [16] (http://prodes.toulouse.inra.fr/multa-
lin/multalin.html) and analysed to identify conserved regions
for the primer design. Primers for the detection of B. paraper-
tussis were designed from the available IS1001 sequence
(GenBank accession number X66858).
Seventy 16S rDNA sequences from diverse bacterial
species found commonly in humans, including Moraxella
catarrhalis, Chlamydia pneumoniae, N. meningitidis, H. inﬂuenzae,
H. parainﬂuenzae, B. pertussis, B. parapertussis, B. holmesii,
B. bronchiseptica, E. coli, Salm. Enteritidis, Salm. Typhimurium,
M. pneumoniae, M. genitalium, Strep. pneumoniae and Staph. au-
reus, were aligned and primers were designed to target a
conserved region. The resulting three primer sets (Table 1)
were designed using the Primer Express software package
(Applied Biosystems, Foster City, CA, USA) and were
synthesised by Eurogentec (Seraing, Belgium).
Real-time PCR and MCA analysis
SYBR Green real-time PCR ampliﬁcation and MCA were
carried out in a ﬁnal volume of 25 lL containing 12.5 lL of
SYBR Green PCR Master Mix (Applied Biosystems), 0.3 lM
each primer and 5 lL of puriﬁed DNA in an ABI PRISM 7000
thermocycler (Applied Biosystems). Ampliﬁcation parameters
comprised 95C for 10 min, followed by 40 cycles of 95C for
15 s and 60C for 1 min. This was followed by the melting
program of the ABI PRISM 7000 thermocycler, with continu-
ous monitoring of the ﬂuorescence (dissociation program).
RESULTS AND DISCUSSION
Development of the assay
The IS481 sequences were chosen because PCRs
targeting these repeated sequences are more
sensitive than PCRs targeting the toxin promoter
[3]. The IS481 primers were designed in order to
avoid primer dimers that could interfere with the
interpretation of the results. A universal PCR
targeting the 16S rRNA gene was also developed
to be used as a control to monitor the extraction
and absence of PCR inhibitors. The PCR primer
sets were tested on DNA extracted from the
Table 1. PCR primers used in this study





F1-BP TCCGAACCGGATTTGAGAAA IS481 60 78.5
R1-BP CCGGGCTCCTTGAGTGAA
F1-BpP ATGCTGGATCGCAAGTTGATG IS1001 81 85.8
R2-BpP TGGGTCTTCGGGCCATT
F1-16S-TQM CGTGTCGTGAGATGTTGGGTTA 16S rDNA 60 78.5
R1-16S-TQM GACGTCATCCCCACCTTCCT
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Bordetella spp. and other bacterial species listed
above. As expected, DNA extracted from all of the
strains yielded PCR products with the F1 ⁄R1-16S-
TQM primer set targeting 16S rRNA genes. Only
DNA extracted from B. pertussis yielded ampliﬁ-
cation products with the F1 ⁄R1-BP primer set,
and only DNA extracted from B. parapertussis
yielded ampliﬁcation products with the F1 ⁄R2-
BpP primer set. MCA of the 60-bp and 81-bp
amplicons from the B. pertussis and B. parapertus-
sis control strains showed melting temperatures
(Tm) of c. 79C and 86C, respectively.
Retrospective study
A retrospective study was performed on culture-
and direct ﬂuorescent antibody test-positive
NPAs (n = 17) and on culture- and direct ﬂuor-
escent antibody test-negative NPAs (n = 12), all of
which were tested undiluted and diluted 1:10.
The expected peak corresponding to B. pertussis
was generated for the 17 positive samples, with
no peak for the 12 negative samples. No addi-
tional peak was ever observed with these two
PCRs, including all of the dilutions tested, or the
specimens tested (water, control strains and
NPA). Even after 40 PCR cycles, no primer dimers
were observed (data not shown).
Sensitivity of the test
The sensitivity of the PCR for the detection of
B. pertussis and B. parapertussis was evaluated
using ten-fold serial dilutions of a bacterial
suspension in phosphate-buffered saline, which
was quantiﬁed by culture on speciﬁc media and
subsequent colony counts. PCR with the DNA
extracted from the bacterial suspensions yielded
regression curves with slopes of )3.379 and
)3.323 for B. pertussis and B. parapertussis, respect-
ively, i.e., very close to a slope of )3.32, which
would correspond to the maximum efﬁciency. For
the two PCRs, the regression curve was linear
from 105 to one bacterial genome with a reaction
volume of 25 lL.
Prospective study
In total, 132 successive clinical specimens re-
ceived at the Hospital of Bordeaux between April
2003 and December 2005 were tested, and the
PCR results were compared with the results of
culture. All of the NPAs gave a positive result
with the 16S rDNA PCR, thereby demonstrating
that DNA extraction from each specimen had
been successful and that the PCR was not inhib-
ited. Of the 132 clinical samples tested, seven
were positive by culture (one B. bronchiseptica and
six B. pertussis), while 22 were positive by PCR for
Bordetella spp. (three B. parapertussis and 19 B. per-
tussis), i.e., three times as many positive results by
PCR than by culture. The identiﬁcation results are
summarised in Table 2.
The results for the seven cases positive by both
culture and PCR were in agreement, with the
exception of one isolate ofB. bronchiseptica thatwas
identiﬁed by culture, but was identiﬁed errone-
ously as B. pertussis by PCR. An identical PCR
result was obtained with genomic DNA extracted
from the puriﬁed isolate, thereby conﬁrming the
presence of IS481 sequences from B. pertussis in
this B. bronchiseptica strain, as reported previously
[17]. The young infant infected by B. bronchiseptica
exhibited clinical symptoms of whooping cough,
but cases of whooping cough associated with
B. bronchiseptica infection are rare and are often
associated with underlying conditions (e.g., im-
munosuppression) [18] or are acquired by contact
with pets vaccinated orally with attenuated strains
[19]. This result indicates a continued need to
maintain cultural techniques in order to follow the
epidemiology ofB. bronchiseptica infections, and an
additional need to monitor the speciﬁcity of IS481
sequences [3] or to use another target gene, e.g., the
toxin promoter region.
Among the 22 PCR-positive cases, there were
three adult women (mean age, 53.6 ± 25.3 years)
and 19 children (male ⁄ female ratio, 0.58; mean
age, 4.8 ± 6.6 months), of whom 82.3% were aged
<6 months. Of the 19 children, 70.6% had not
been vaccinated, and 17.6% had received only
Table 2. Culture and PCR identiﬁcation results for Borde-
tella spp. among 132 nasopharyngeal aspirate samples
included in the prospective study
Number of patients Culture-positive PCR-positive
110 Negative Negative
3 Negative B. parapertussis
12a Negative B. pertussis
6b B. pertussis B. pertussis
1c B. bronchiseptica B. pertussis
Total = 132 (7 positive) (22 positive)
a,bThese groups contain one and two nasopharyngeal aspirate samples, respect-
ively, taken from adults.
cConﬁrmed as B. bronchiseptica by 16S rDNA sequencing and by the French
National Reference Centre for Bordetella, although the PCR (on nasopharyngeal
aspirates and on the puriﬁed isolate) was positive for B. pertussis.
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one dose of vaccine; the vaccination status was
unknown for 11.8% cases. These children were
admitted to the hospital for a progressive cough,
which began <8 days before admission in 17.7%
of cases and ‡8 days before admission in 82.3% of
cases. The cough continued to evolve over
>21 days in 58.8% of these cases. Among the
more serious symptoms, 29% of the children
suffered from periods of apnoea, and 17.7% of the
children were admitted to the intensive care unit.
A hyper-lymphocytosis was detected in 29.4% of
cases, and a respiratory syncytial virus co-infec-
tion was detected in one case. All of the children
were treated with macrolides; overall, the clinical
outcome was positive, but one infant died. In
41.2% of the cases, a contaminant organism
(either suspected or proven) was identiﬁed and,
furthermore, was found in 85.7% of the families
of these children.
The infant who died was unvaccinated and was
aged 2.5 months. He was admitted to the paediat-
ric intensive care unit in June 2005 for respiratory
distress, with a 3-day history of a progressive
cough, despite treatment with josamycin. Severe
hypoxaemia and signiﬁcant pulmonary arterial
hypertension were observed upon admission. Ini-
tial laboratory tests revealed a white blood cell
count of 118 Giga ⁄L (66% segmented neutrophils
and 26% lymphocytes) and a platelet count of
768 Giga ⁄L. A chest X-ray showed bilateral and
complete densities in the lungs. An NPA was
negative for pertussis by culture, but the PCR was
positive for B. pertussis, which supported the diag-
nosis of malignant whooping cough and elimin-
ated the possibility of haematological disease.
NPAs from the parents were negative by culture,
but the NPA from the mother, aged 23 years, was
positive by PCR. The mother had complained of a
simple cough 15 days earlier. Despite assisted
ventilation, the child died 17 days after admission
to the paediatric intensive care unit.
Although this malignant form of pertussis
remains very rare, it is always a severe disease
in infancy. This case illustrates: (i) the importance
of PCR in the diagnosis of whooping cough,
considering the limitations of culture [3], especi-
ally in atypical cases and after initiation of an
antibiotic treatment; (ii) the need to identify
carriers in order to avoid further infections in
the community and to establish an epidemiolog-
ical link; and (iii) the importance of the recent
changes in the French immunisation schedule,
including the recommendation of a pertussis
vaccine booster for young adults, particularly at
the time of pregnancy [20].
Nucleic acid ampliﬁcation tests are now in-
creasingly relevant for the detection and identiﬁ-
cation of B. pertussis and B. parapertussis,
particularly in view of the lack of sensitivity of
culture for detecting these bacteria. Three real-
time PCR detection formats are available (SYBR
Green, TaqMan or ﬂuorescence resonance energy
transfer chemistries). The SYBR Green format has
the advantage of being implemented easily on
different real-time PCR machines. Two PCRs
using SYBR Green and MCA of the resulting
amplicons have been described previously for
detection of B. pertussis and B. parapertussis. The
ﬁrst of these, targeting the promoter of the toxin
subunit S1 of B. pertussis and the toxin pseudo-
gene of B. parapertussis [15], generated PCR prod-
ucts with Tms of 89.8C and 91.7C, respectively,
but also generated non-speciﬁc products with a Tm
of c. 81C, probably corresponding to double-
stranded primer dimers, that interfered with the
interpretation and ⁄ or quantiﬁcation. Moreover,
this PCR was less sensitive than a second PCR
targeting the IS481 and IS1001 repeated sequences
of B. pertussis and B. parapertussis [3,11], although
the latter PCR also generated non-speciﬁc prod-
ucts. The PCR described in the present study also
targets the IS elements of these bacteria, but no
non-speciﬁc peaks were ever detected, and the
sensitivity level was comparable to those reported
previously using either SYBR Green and MCA
[11], a ﬂuorescence resonance energy transfer
probe [7] or a TaqMan probe [8]. It should be
noted that the presence of repeated IS elements
means that PCRs speciﬁcally targeting such ele-
ments are often more sensitive, but the fact that
these sequences are also transposable elements
[21] may reduce the speciﬁcity. Indeed, a fragment
from IS481 has been detected in B. holmesii [22] as
well as in B. bronchiseptica (this study). These
observations suggest that complementary PCRs
targeting a speciﬁc gene, e.g., the toxin or the
pertactin genes [12–14], may be useful in provi-
ding support for interpretation of the assay result.
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